Cooley advised Bellicum Pharmaceuticals on its $69 million public offering of 5,750,000 shares of common stock, including the exercise by the underwriters of their option to…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
